Oakhouse Partners

Oakhouse Partners is a San Francisco-based venture capital firm established in 2020, dedicated to investing in companies that leverage breakthrough technologies to profoundly enhance millions of lives. The firm distinguishes itself by targeting innovative solutions across critical sectors, aiming to support foundational advancements rather than incremental improvements. Their investment thesis centers on identifying and nurturing ventures poised to create significant, long-term societal impact through scientific and technological innovation.

The firm primarily focuses its investments on Seed and Series A stage companies, demonstrating a commitment to early-stage ventures with high growth potential. Oakhouse Partners is known for its hands-on approach, typically leading or co-leading investment rounds and often securing a board seat to actively guide portfolio companies. Their strategic focus spans four core areas: Health & Human Longevity, which includes biotech and health tech; Sustainable Systems, addressing environmental and resource challenges; Human-Computer Interaction, exploring the evolving relationship between people and technology; and Frontier Technologies, encompassing nascent but disruptive fields like advanced materials or space tech.

With a portfolio that includes over 20 investments since its inception, Oakhouse Partners has established itself as a significant player in the deep tech investment landscape. The firm emphasizes building long-term partnerships with founders, providing not just capital but also strategic support through various growth phases. While specific check sizes can vary based on the round and company needs, Oakhouse Partners typically deploys first checks ranging from approximately $1 million for Seed rounds to up to $8 million for Series A investments, reflecting their role as a lead investor in capital-intensive, high-potential technology companies.